Jan 25, 2023
New report analyzes patient impact of game-changing biosimilars, including the introduction of competing biosimilars for Humira WASHINGTON — Patients Rising, a non-profit organization advocating on behalf of patients with chronic and rare diseases, today released...
Oct 20, 2022
On October 11, 2022 2021, ICER released a draft evidence report, “Fezolinetant for Moderate to Severe Vasomotor Symptoms Associated with Menopause.” This is the first step in ICER’s assessment process that is current scheduled to conclude with the release of a final...
Oct 12, 2022
By Terry WilcoxCo-founder and CEO, Patients Rising My grandmother lived at the top of a hill overlooking the magical mountains and valleys of the Ozarks until the day we literally had to drag her off of it. Our family was spread out across Texas and California working...
Sep 28, 2022
On September 13, 2022 2021, ICER released a new draft evidence report, “Gene Therapy for Hemophilia B and An Update on Gene Therapy for Hemophilia A.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in December...
Jul 25, 2022
On July 13, 2022 2021, ICER released its draft evidence report, “Medications for Obesity Management.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in October 2022. ICER’s report reviews four medicines...
